Skip to main content

dupilumab (Dupixent®)

 

Following a limited submission

AWMSG advice

Status: Recommended with restrictions

Dupilumab (Dupixent®) is recommended as an option for restricted use within NHS Wales.

Dupilumab (Dupixent®) is licensed for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy.

Dupilumab (Dupixent®) is restricted for the treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy and where existing systemic therapies are not advisable.

Dupilumab (Dupixent®) is not recommended for use within NHS Wales outside of this subpopulation.

This recommendation applies only in circumstances where the approved Patient Access Scheme (PAS) is utilised or where the list/contract price is equivalent or lower than the PAS price.

 Final Recommendation: dupilumab (Dupixent) 3858 FAR (PDF, 341Kb)
 Appraisal Report: dupilumab (Dupixent®) 3858 (PDF, 115Kb)

Medicine details

Medicine name dupilumab (Dupixent®)
Formulation 200 mg and 300 mg solution for injection
Reference number 3858
Indication

Treatment of severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy

Company Sanofi
BNF chapter Skin
Submission type Limited
Status Recommended with restrictions
Advice number 0221
NMG meeting date 06/01/2021
AWMSG meeting date 09/02/2021
Date of issue 17/03/2021
Commercial arrangement PAS